Apimeds Pharmaceuticals (APUS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing Apitox, a bee venom-based biologic for osteoarthritis (OA) and multiple sclerosis (MS).

• Holds exclusive U.S. rights to Apitox via a sublicensable, royalty-bearing license from Apimeds Korea.

• Apitox is not FDA-approved; prior clinical success in South Korea but U.S. approval requires further Phase III trials.

• Focused on advancing Apitox for advanced knee OA and exploring MS through non-registered studies.

• No U.S. product revenue to date; operations funded by equity and related party loans.

Financial performance and metrics

• No revenue generated as of September 30, 2024.

• Net loss of $1,078,357 for the nine months ended September 30, 2024; $777,694 net loss for 2023.

• Cash balance of $26,571 as of September 30, 2024; accumulated deficit of $4,080,291.

• Operating expenses driven by increased general and administrative costs, especially pre-IPO professional fees.

• Auditor’s report includes a going concern warning due to recurring losses and limited cash runway.

Use of proceeds and capital allocation

• Estimated net proceeds of $8.8 million (up to $10.2 million with full over-allotment) at $3.00/share IPO price.

• Proceeds to fund Phase III knee OA trial (~$6.5M), initiate MS study (~$1M), manufacturing (~$1M), repay short-term debt, and for working capital.

• Funds expected to support operations for at least 12 months post-offering.